論文・技術情報追加のお知らせ

1. Hematopoietic adverse events associated with PARP Inhibitors:A FAERS database study.

PARP阻害薬の血液障害副作用、監視が重要

対象DB：FAERS

2. Analysis of the relationship between antineoplastic drugs and suicide-related adverse events based on the food and drug administration adverse event reporting system database.

抗がん剤と自殺関連副作用の関連性は低い

対象DB：FAERS

3. Signal detection and analysis of adverse events associated with Genvoya((R)) based the FAERS database.

ゲンボイヤ使用に関する新たな副作用リスクを発見

対象DB：FAERS

4. T-Cell malignancies following CAR T-Cell therapy: insights from the FDA adverse event reporting system (FAERS).

CAR-T療法でT細胞リンパ腫の報告頻度が高い

対象DB：FAERS

5. Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS).

T-VEC治療における新たな安全性シグナルを検出

対象DB：FAERS

6. Data mining in FAERS: association of newer-generation H1-antihistamines with nervous system disorders.

新世代H1抗ヒスタミン薬における神経系副作用の比較分析

対象DB：FAERS

7. A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab.

ダルバルマブ免疫療法に関連する副作用に注意

対象DB：FAERS

8. Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS.

ゾレドロン酸の腎・尿路障害に注意が必要

対象DB：FAERS

9. Adverse drug events associated with metreleptin administration: a real-world pharmacovigilance study from 2014 to 2024 using the FAERS database.

メトレレプチンの有害事象で新たなリスクが確認された

対象DB：FAERS

10. Cardiovascular Events Associated with CDK4/6 Inhibitors: A Safety Meta-Analysis of Randomized Controlled Trials and a Pharmacovigilance Study of the FAERS Database.

CDK4/6阻害薬は心血管有害事象のリスク増加

対象DB：FAERS

11. The antidepressants and sexual dysfunction: a pharmacovigilance-pharmacodynamic study of the FDA adverse event reporting system.

抗うつ薬の性機能障害に関する新たなシグナルを確認

対象DB：FAERS

12. SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review.

COVID-19ワクチンは有益であり、副作用リスクは低い

対象DB：FAERS,VAERS

13. Postmarketing Safety Surveillance of Topiramate: A Signal Detection and Analysis Study Based on the FDA Adverse Event Reporting System Database.

トピラマートは新たな重篤な副作用があり、慎重な監視が必要

対象DB：FAERS

14. Adverse events of nusinersen: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.

ヌシセルセンは新たな副作用リスクがあり、特に若年層と高齢者に注意が必要

対象DB：FAERS

15. Thrombotic Microangiopathy Associated with Calcineurin Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.

タクロリムスは血栓微小血管症(TMA)リスクが高く、地域や性別差も影響

対象DB：FAERS

16. Assessment of distributions and gender difference in adverse events related to faricimab: a real-world study based on FDA adverse event reporting system.

ファリシマブは眼科及び非眼科の副作用があり、性別差も存在

対象DB：FAERS

17. Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases.

オメガ3脂肪酸が免疫チェックポイント阻害剤によるILDのリスク低減に有望

対象DB：FAERS,JADER

18. Trailblazing real-world-data to confront hepatocellular carcinoma - disinterring repurposable drugs by amalgamating avant-garde stratagems.

リアルワールドデータで肝細胞癌の再利用可能薬を探索

対象DB：FAERS

19. The Role of Patient- and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System.

経口ミノキシジルと心膜水腫の関連分析

対象DB：CVAR,FAERS

20. Cutaneous toxicity induced by antidepressants and second-generation antipsychotics in the United States food and drug administration adverse event reporting system.

抗うつ薬と抗精神病薬の皮膚毒性分析

対象DB：FAERS

21. The safety profile of azithromycin in pediatrics: a pharmacovigilance disproportionality analysis.

小児におけるアジスロマイシンの副作用に関する分析

対象DB：FAERS

22. Interactions of warfarin with COVID-19 vaccine/drugs, monoclonal antibodies, and targeted anticancer agents from real-world data mining.

ワルファリンとの薬剤相互作用に関する実データ分析

対象DB：FAERS,VAERS

23. Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment.

免疫介在性疾患治療薬で逆説的IBDのリスクあり

対象DB：FAERS

24. Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FDA Adverse Event Reporting System (FAERS).

HER2陽性乳癌患者にT-DCsで心血管イベントの監視が必要

対象DB：FAERS

25. Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.

BRAFi + MEKi療法で神経学的副作用が確認された

対象DB：FAERS

26. Drug-induced dementia: a pharmacovigilance analysis of the FAERS database.

タムスロシンやアルフゾシンが認知症リスクを高める可能性

対象DB：FAERS

27. Real-world study of isavuconazole adverse events based on pharmacovigilance spontaneous reporting systems.

イサフコナゾールは肝障害の報告が多く、注意が必要

対象DB：EudraVigilance,VigiBase

28. Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database.

TKI治療は心毒性リスクがあり、個別の評価が必要

対象DB：VigiBase

29. A Comparative Analysis of Nursing Care Needs Scores at Discharge and Transfer Among Survivors of Critical COVID-19 and Septic Shock: A Retrospective Observational Study Using Modified Poisson Regression From Japan.

COVID-19患者は退院時の看護ケアニーズが高い

対象DB：DPC

30. Persistence of advanced therapies in patients with inflammatory bowel disease: retrospective cohort study using a large healthcare claims database in Japan.

日本のIBD患者における治療薬の継続率を報告

対象DB：JMDC

31. Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer.

抗アンドロゲン受容体シグナル阻害薬の使用と医療費が増加

対象DB：NDB

32. Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study.

アテゾリズマブ併用療法で発熱性好中球減少症の発生率が高い

対象DB：MDV

33. Tackling algorithmic bias and promoting transparency in health datasets: the STANDING Together consensus recommendations.

AI健康技術のバイアスを避けるため、データの透明性と公平性評価が重要

対象DB：CPRD

34. Involving People With Lived Experience in Electronic Health Record Database Studies Reflections and Learning From the CHOOSE Study.

電子カルテデータ研究における患者参加の課題と利点

対象DB：CPRD

35. Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000-2019: 20-year investigation of who receives treatment, with which agents and at what doses.

抗精神病薬処方は主に4薬剤、用量や処方に群間格差が存在

対象DB：CPRD

36. Obstructive sleep apnoea syndrome and future risk of dementia among individuals managed in UK general practice.

OSASは認知症リスク増加と関連、CPAP治療効果は不明

対象DB：CPRD

37. Mortality Trends and Causes of Death in Myotonic Dystrophy Type 1 Patients From the UK Clinical Practice Research Datalink.

DM1患者の死亡リスクは高く、呼吸不全が主な死因。対策が必要

対象DB：CPRD

38. Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population-based cohort study.

メトホルミンはGDM治療でインスリンより妊娠合併症リスクを低減

対象DB：CPRD

39. Resource availability and capacity to implement multi-stranded cholera interventions in the north-east region of Nigeria.

ナイジェリアでコレラ対策資源に地域差、監視や地域連携の強化が課題

対象DB：CPRD

40. Application of a Language Model Tool for COVID-19 Vaccine Adverse Event Monitoring Using Web and Social Media Content: Algorithm Development and Validation Study.

SNS解析でCOVID-19ワクチン有害事象を早期検出し、安全性監視を強化

対象DB：CVAR

41. Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan.

日本のES-SCLC治療で抗PD-L1療法が普及も、生存率は依然低く、未解決の医療ニーズが残る

対象DB：DeSC